📁Pharma Team / Shared drive

Launch sequencing assumes Q2 formulary parity at top-3 PBMs. Field deployment at 142 reps across 6 regions.

WK19 NBRx -14.1% in Northeast — UHC PA latency now the dominant gap-to-plan driver.

Tier 1 HCPs require 2x reach/quarter with peer-to-peer + MSL touch. Replaces v3.1 RTE cadence after Q1 effectiveness review.

Boston and NYC tracking 112% to plan; Philadelphia at 84% pending two large IDN pull-throughs. Two open territories filling June 1.